Neoantigen Dendritic Cell Vaccine
Liver Cancer, Adult
Chinese PLA General HospitalvaccinePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
112 Active assets in the Liver Cancer, Adult cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bxcl501 Uppsala University Hospital | Phase 4 | BBB |
Inno-206 Shanghai Zhongshan Hospital | Phase 4 | BB |
Eloxatin Sun Yat-sen University | Phase 3 | BB |
Sorafenib First Affiliated Hospital Xi'an Jiaotong University | Phase 3 | BB |
Idarubicine Second Affiliated Hospital of Guangzhou Medical University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Neoantigen Dendritic Cell Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →